Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer ...
Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on ...
On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...
MedPage Today on MSN
For Your Patients: A Look at Promising New Treatments for Gastric Cancer
Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...
Junior research group leader Dr. Anne Fassl from the Department of Urology at Universitätsmedizin Frankfurt has been awarded a Young Investigator Award 2025 by the U.S.-based Prostate Cancer ...
Lilly inks gene therapy deal with Seamless Therapeutics to develop programmable recombinase treatments targeting genetic hearing loss worldwide.
Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline ...
Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results